GoldCoast Resource Corp. (PSYGD)
| Market Cap | 6.48M +236.5% |
| Revenue (ttm) | n/a |
| Net Income | -2.37M |
| EPS | -0.33 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94 |
| Open | 0.8696 |
| Previous Close | 0.7947 |
| Day's Range | 0.8696 - 0.8835 |
| 52-Week Range | 0.4800 - 2.8070 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About GoldCoast Resource
GoldCoast Resource Corp. engages in the exploration of gold deposits in Ghana. The company is based in Toronto, Canada. [Read more]
News
Psyence Group Announces Name Change, Share Consolidation and Closing of RTO with GoldCoast Resource Corp.
TORONTO, ON / ACCESS Newswire / July 28, 2026 / GoldCoast Resource Corp. (formerly, Psyence Group Inc.) (CSE:PSYG) (the "Company") is pleased to announce that it has completed its previously announced...
Psyence Group Inc. Announces Results of Annual General and Special Meeting of Shareholders
TORONTO, ON / ACCESS Newswire / May 21, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce the voting results from its annual general and special meeting of share...
Psyence Group Inc. Announces Amendment to Amalgamation Agreement with GoldCoast Resource Corp.
TORONTO, ON / ACCESS Newswire / April 23, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce that it has entered into an amendment dated April 13, 2026 (the "Amen...
Psyence Group Announces GoldCoast Resource Closes Second Tranche of Offering
Combined aggregate with previous tranche of $8,603,883 TORONTO, ON / ACCESS Newswire / March 24, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that GoldCoast Resource Cor...
Psyence Group Inc. Provides Update on Proposed Amalgamation with GoldCoast Resource Corp.
GoldCoast Closes First Tranche of Private Placement TORONTO, ON / ACCESS Newswire / March 17, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that GoldCoast Resource Corp. ...
Psyence Group Inc. Enters into Amending Agreement to Extend Amalgamation Timeline with GoldCoast Resource Corp.
TORONTO, ON / ACCESS Newswire / February 24, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that it has entered into an amending agreement (the "Amending Agreement") dated...
Psyence Group's RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana's Shallow Continental Shelf
TORONTO, ON / ACCESS Newswire / January 27, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that its proposed reverse takeover target, GoldCoast Resource Corp. ("GoldCoast"...
CSE Bulletin: Halted for Fundamental Change - Psyence Group Inc. (PSYG)
Toronto, Ontario--(Newsfile Corp. - Le 24 novembre/November 2025) - Trading in the shares of Psyence Group Inc. (PSYG) will remain halted pending receipt and review of acceptable documentation regardi...
Psyence Group Inc. Enters into Amalgamation Agreement with Goldcoast Resource Corp.
TORONTO, ON / ACCESS Newswire / November 24, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce that, further to its news release dated August 22, 2025, it has en...
Psyence Group Inc. Announces RSU Grants
TORONTO, ON / ACCESS Newswire / October 17, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it granted an aggregate of 721,448 restricted share units (each an "RSU") ...
Psyence Group Inc. Enters Into a Letter of Intent to Acquire Goldcoast Resource Corp.
TORONTO, ON / ACCESS Newswire / August 22, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it has entered into a letter of intent (the "LOI") to acquire all of the is...
Psyence Group Inc. Closes Second Tranche of Non‑Brokered Private Placement for Remaining Proceeds
TORONTO, ON / ACCESS Newswire / July 7, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), is pleased to announce that it has successfully closed the second tranche ("Tranche 2") of it...
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psilocybin in mental health a...
PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares
TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental h...
CSE Bulletin: Consolidation - Psyence Group Inc. (PSYG)
Toronto, Ontario--(Newsfile Corp. - Le 21 avril/April 2025) - Psyence Group Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated com...
Psyence Group Announces Share Consolidation
TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share ...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or...
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt-for-e...
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustmen...
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the "Debt Swap A...
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being PsyLabs develops and produces certified pharmaceutical-grade natural ...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and ...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and w...